Last reviewed · How we verify
teverelix TFA
At a glance
| Generic name | teverelix TFA |
|---|---|
| Sponsor | Antev Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Teverelix Evaluated in Advanced Prostate Cancer (PHASE2)
- A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- teverelix TFA CI brief — competitive landscape report
- teverelix TFA updates RSS · CI watch RSS
- Antev Ltd. portfolio CI